Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  European Journal of Cancer

• Publication date

  1999-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0959-8049(99)00132-XPMID 10658533
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cell Growth Inhibition by Farnesyltransferase Inhibitors Is Mediated by Gain of Geranylgeranylated RhoB

  1999cited by this paper
• Non-Ras targets of farnesyltransferase inhibitors: focus on Rho

  1998cited by this paper
• A Farnesyltransferase Inhibitor Induces Tumor Regression in Transgenic Mice Harboring Multiple Oncogenic Mutations by Mediating Alterations in Both Cell Cycle Control and Apoptosis

  1998cited by this paper
• K-ras is an essential gene in the mouse with partial functional overlap with N-ras.

  1997cited by this paper
• Farnesyl transferase inhibitors induce apoptosis of Ras-transformed cells denied substratum attachment.

  1997cited by this paper
• Treating cancer by inhibiting angiogenesis: new hopes and potential pitfall

  1996cited by this paper
• Tumor angiogenesis: A physiological process or genetically determined?

  1996cited by this paper
• Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.

  1996cited by this paper
• A model of angiogenesis in the mouse cornea.

  1996cited by this paper
• Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

  1995cited by this paper
• Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.

  1995cited by this paper
• Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity

  1995cited by this paper
• VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines.

  1995cited by this paper
• A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.

  1995cited by this paper
• Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

  1995cited by this paper
• Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*)

  1995cited by this paper
• Consequences of angiogenesis for tumor progression, metastasis and cancer therapy.

  1995cited by this paper
• Oncogenes as inducers of tumor angiogenesis

  1995cited by this paper
• Both v-Ha-Ras and v-Raf Stimulate Expression of the Vascular Endothelial Growth Factor in NIH 3T3 Cells (*)

  1995cited by this paper
• Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression

  1995cited by this paper
• Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.

  1994cited by this paper
• Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant

  1994cited by this paper
• The regulation of endothelial cell motility by p21 ras.

  1994cited by this paper
• Thalidomide is an inhibitor of angiogenesis.

  1994cited by this paper
• Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells.

  1993cited by this paper
• Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

  1993cited by this paper
• Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro

  1993cited by this paper
• Function and regulation of ras.

  1993cited by this paper
• How receptors turn Ras on

  1993cited by this paper
• Anti-Ras drugs come of age.

  1993cited by this paper
• Signal transduction. How receptors turn Ras on.

  1993cited by this paper
• The role of p21ras in receptor tyrosine kinase signaling.

  1993cited by this paper
• Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.

  1993cited by this paper
• Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

  1992cited by this paper
• Assay and purification of naturally occurring inhibitor of angiogenesis.

  1991cited by this paper
• Regulators and effectors of ras proteins.

  1991cited by this paper
• A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane.

  1990cited by this paper
• Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor.

  1990cited by this paper
• ras genes.

  1987cited by this paper
• The p21 ras C-terminus is required for transformation and membrane association

  1984cited by this paper
• Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors

  1972cited by this paper

• Peptidomimetics in cancer targeting

  2022cites this paper
• Autism genes are selectively targeted by environmental pollutants including pesticides, heavy metals, bisphenol A, phthalates and many others in food, cosmetics or household products

  2016cites this paper
• Lonafarnib Is a Potential Inhibitor for Neovascularization

  2015cites this paper
• in therapy Farnesyltransferase inhibitors in hematologic malignancies: new horizons

  2013cites this paper
• leukemia and other hematologic malignancies Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid

  2013cites this paper
• The Farnesyltransferase Inhibitor LB42708 Suppresses Vascular Endothelial Growth Factor-Induced Angiogenesis by Inhibiting Ras-dependent Mitogen-Activated Protein Kinase and Phosphatidylinositol 3-Kinase/Akt Signal Pathways

  2010cites this paper
• Novel aspects of corneal angiogenic and lymphangiogenic privilege.

  2010cites this paper
• The Farnesyltransferase Inhibitor LB42708 Suppresses VEGF-induced Angiogenesis by Inhibiting Ras-dependent MAPK and PI3K/Akt Signal Pathways

  2010cites this paper
• Chapter 222 – Farnesyltransferase Inhibitors

  2010cites this paper
• Microwave-assisted synthesis of novel (5-nitropyridin-2-yl)alkyl and (5-nitropyridin-3-yl)alkyl carbamates.

  2009cites this paper
• Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?

  2008cites this paper
• Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis

  2008cites this paper
• Development of Farnesyltransferase Inhibitors for Clinical Cancer Therapy: Focus on Hematologic Malignancies

  2007cites this paper
• Farnesyl Transferase Inhibitors in the Therapy of AML

  2007cites this paper
• Combining a matrix metalloproteinase inhibitor, a farnesyltransferase inhibitor, and a taxane improves survival in an anaplastic thyroid cancer model.

  2006cites this paper
• Chapter 7 Preclinical studies of chemotherapy for undifferentiated thyroid carcinoma

  2006cites this paper
• A disconnect between antitumor and antiangiogenic effects of fluvastatin in vitro and in vivo.

  2006cites this paper
• Development of the farnesyltransferase inhibitor tipifarnib for therapy of hematologic malignancies.

  2005cites this paper
• Potent farnesyltransferase inhibitor ABT-100 abrogates acute allograft rejection.

  2005cites this paper
• A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

  2005cites this paper
• Targeting the process of farynesylation for therapy of hematologic malignancies.

  2005cites this paper
• Farnesyltransferase inhibitor effects on prostate tumor micro‐environment and radiation survival

  2005cites this paper
• Changes in endosome-lysosome pH accompanying pre-malignant transformation.

  2005cites this paper
• Farnesyltransferase inhibitors: recent advances

  2004cites this paper
• Cancer anti-angiogenic therapy.

  2004cites this paper
• Oncogenes and Tumor Angiogenesis

  2004cites this paper
• Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer.

  2004cites this paper
• Stimulation of angiogenesis by Ras proteins.

  2004cites this paper
• p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells.

  2003cites this paper
• Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy.

  2003cites this paper
• The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.

  2003cites this paper
• Farnesyltransferase Inhibitors as Anticancer Agents

  2003cites this paper
• Anaplastic Thyroid Cancer Cells p21 Waf-1 (Cip-1) Enhances Apoptosis Induced by Manumycin and Paclitaxel in

  2003cites this paper
• Regulation of endothelial cell differentiation and transformation by H-Ras.

  2003cites this paper
• Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations.

  2003cites this paper
• Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf

  2003cites this paper
• Preclinical and Clinical Investigations Farnesyltransferase Inhibitors : An Overview of the Results of Updated

  2003cites this paper
• Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

  2003cites this paper
• The role of farnesyltransferase inhibitors in lung cancer therapy.

  2002cites this paper
• Farnesyltransferase Inhibitors in Breast Cancer Therapy

  2002cites this paper
• Farnesyltransferase inhibitors: promises and realities.

  2002cites this paper
• Peptidomimetics and angiogenesis.

  2002cites this paper
• Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs.

  2002cites this paper
• Protein farnesyltransferase inhibitors.

  2002cites this paper
• Geranylgeranylated RhoB Mediates the Apoptotic and Antineoplastic Effects of Farnesyltransferase Inhibitors

  2002cites this paper
• Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma.

  2001influential citation
• Farnesyltransferase inhibitors: mechanism and applications

  2001cites this paper
• The Farnesyltransferase Inhibitor L 744 , 832 Reduces Hypoxia in Tumors Expressing

  2001cites this paper
• The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.

  2001cites this paper
• Ras regulation of vascular endothelial growth factor and angiogenesis.

  2001cites this paper
• 4 Farnesyltransferase inhibitors

  2001cites this paper
• Current status of clinical trials of farnesyltransferase inhibitors

  2001cites this paper
• Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.

  2000cites this paper
• Inhibitors of prenylation of Ras and other G-proteins and their application as therapeutics.

  2000cites this paper
• Oncogenes and angiogenesis: signaling three-dimensional tumor growth.

  2000cites this paper
• 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.

  2000cites this paper
• Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines.

  1999cites this paper